# Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

> **NCT02243007** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 7 (actual)

## Conditions studied

- Resectable Pancreatic Cancer
- Pancreatic Ductal Carcinoma

## Interventions

- **DRUG:** FOLFIRINOX
- **DRUG:** Gemcitabine/nab-Paclitaxel
- **RADIATION:** Radiation therapy
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02243007
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243007, "Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02243007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*